Paolo Silvani

Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial

Maria Sessa, Laura Lorioli, Francesca Fumagalli et al. · The Lancet · 2016 · 507 citations

Medicine, Hematology, Molecular Medicine +13

Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access

Francesca Fumagalli, Valeria Calbi, Maria Grazia Natali Sora et al. · The Lancet · 2022 · 284 citations · Full text

Medicine, Hematology, Immunology +15

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy

Alberto Zangrillo, Luigi Beretta, Anna Mara Scandroglio et al. · Critical Care and Resuscitation · 2020 · 260 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +17

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency

Alberto Zangrillo, Luigi Beretta, Paolo Silvani et al. · Critical Care and Resuscitation · 2020 · 229 citations · Full text

Medicine, Emergency Medicine, Infectious Diseases +17

Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study

Francesca Ferrua, Maria Pia Cicalese, Stefania Galimberti et al. · The Lancet Haematology · 2019 · 208 citations · Full text

Medicine, Hematology, Immunology +15